- Multitarget stool-based tests are emerging as promising alternatives for colorectal cancer (CRC) screening in average-risk individuals, potentially surpassing the current standard fecal immunochemical test (FIT).
- These new tests, while similar to FIT in principle, extend their scope by incorporating additional DNA, RNA, or protein biomarkers associated with CRC for enhanced early detection.
- Current CRC screening recommendations include standard FIT, stool FIT-DNA, and guaiac fecal occult blood test (gFOBT), each with its limitations such as false positives and cost concerns.
- Three new multitarget tests under investigation — Cologuard 2.0 (DNA-based), ColoSense (RNA-based), and CRCbioscreen (protein-based) — show promise in improving sensitivity for CRC and advanced precancerous lesions.
What to Know About the Next-Gen FIT for CRC Screening (Medscape)
0
Add A Comment